Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

562 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.
Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Kappos L, et al. Among authors: antel j. Nat Med. 2000 Oct;6(10):1176-82. doi: 10.1038/80525. Nat Med. 2000. PMID: 11017151 Clinical Trial.
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group. Comi G, et al. Among authors: antel j. Mult Scler. 2010 Feb;16(2):197-207. doi: 10.1177/1352458509357065. Epub 2009 Dec 22. Mult Scler. 2010. PMID: 20028707 Clinical Trial.
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Mayo L, Trauger SA, Blain M, Nadeau M, Patel B, Alvarez JI, Mascanfroni ID, Yeste A, Kivisäkk P, Kallas K, Ellezam B, Bakshi R, Prat A, Antel JP, Weiner HL, Quintana FJ. Mayo L, et al. Among authors: antel jp. Nat Med. 2014 Oct;20(10):1147-56. doi: 10.1038/nm.3681. Epub 2014 Sep 14. Nat Med. 2014. PMID: 25216636 Free PMC article.
Natalizumab effects on immune cell responses in multiple sclerosis.
Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand'Maison F, Bar-Or A. Niino M, et al. Ann Neurol. 2006 May;59(5):748-54. doi: 10.1002/ana.20859. Ann Neurol. 2006. PMID: 16634035 Clinical Trial.
Microglial control of astrocytes in response to microbial metabolites.
Rothhammer V, Borucki DM, Tjon EC, Takenaka MC, Chao CC, Ardura-Fabregat A, de Lima KA, Gutiérrez-Vázquez C, Hewson P, Staszewski O, Blain M, Healy L, Neziraj T, Borio M, Wheeler M, Dragin LL, Laplaud DA, Antel J, Alvarez JI, Prinz M, Quintana FJ. Rothhammer V, et al. Among authors: antel j. Nature. 2018 May;557(7707):724-728. doi: 10.1038/s41586-018-0119-x. Epub 2018 May 16. Nature. 2018. PMID: 29769726 Free PMC article.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. Hauser SL, et al. Among authors: antel j. N Engl J Med. 2008 Feb 14;358(7):676-88. doi: 10.1056/NEJMoa0706383. N Engl J Med. 2008. PMID: 18272891 Free article. Clinical Trial.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Kappos L, et al. Among authors: antel j. N Engl J Med. 2006 Sep 14;355(11):1124-40. doi: 10.1056/NEJMoa052643. N Engl J Med. 2006. PMID: 16971719 Free article. Clinical Trial.
562 results